Antihemophilic factor, recombinant, manufactured protein-free; Antihemophilic factor, recombinant, manufactured protein-free
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00243386/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 7–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 82 чел. во всех странах исследования.
- Плановая дата окончания (06.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 10
Критерии включения
- The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level <= 2% of normal, as tested at screening
- The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant)
- The subject is within 7 to 65 years of age
- The subject has a Karnofsky performance score > (greater than) 60
- The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4 count >= 400 cells/mm³ (CD4 count determined at screening, if necessary)
- The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment
- The subject has a documented history (e.g. in medical charts or dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment
- The subject resides within the coverage area of the mobile compliance device; coverage area will be determined at screening
- The subject or the subject's legally authorized representative has provided written informed consent
Критерии невключения
- The subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins
- The subject has a history of factor VIII inhibitors with a titer >= 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening
- The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (by Nijmegen Assay) in the central laboratory
- The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
- The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)
- The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug.
- The subject has participated in another investigational study within thirty (30) days of enrollment
- The subject has previously participated in a clinical study with rAHF-PFM
- The subject's clinical condition may require a major surgery (defined as moderate to critical risk and perioperative blood loss ≥ 500 mL) during the period of the subject's participation in the study
- The subject is female of childbearing potential with a positive pregnancy test
Источник: ClinicalTrials.gov, NCT00243386 · запись обновлена в реестре 19 мая 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 26
- Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens — 12 months ±2 weeks
- Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens — 12 months ±2 weeks
Цель исследования
The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6 hours; actual dose determined by Baxter utilizing an algorithm and the patient's pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled patients will be treated originally on demand for a period of 6 months and then they will be randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of 12 months +/- 2 weeks.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00243386 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.